OSE Immunotherapeutics SA (EPA:OSE)
France
· Delayed Price · Currency is EUR 4.018
-0.042 (-1.03%)
Mar 6, 2026, 5:35 PM CET
OSE Immunotherapeutics Employees
OSE Immunotherapeutics had 64 employees as of December 31, 2024. The number of employees increased by 9 or 16.36% compared to the previous year.
Employees
64
Change (1Y)
9
Growth (1Y)
16.36%
Revenue / Employee
€27,844
Profits / Employee
€508,109
Market Cap
90.09M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Sensorion | 68 |
| ABIONYX Pharma | 51 |
| Adocia | 77 |
| Valerio Therapeutics Société anonyme | 25 |
| MaaT Pharma | 65 |
| Innate Pharma | 174 |
| THX Pharma Société Anonyme | 10 |
| Nicox | 5 |
OSE Immunotherapeutics News
- 4 days ago - OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi® - GlobeNewsWire
- 5 weeks ago - OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab - GlobeNewsWire
- 6 weeks ago - OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) - GlobeNewsWire
- 3 months ago - OSE Immunotherapeutics SA (ORPOF) Discusses Strategic Plan With Four Opportunities for Value Creation Transcript - Seeking Alpha
- 3 months ago - OSE Immunotherapeutics Unveils 2026-2028 Strategic Plan With Four Value-Creating Opportunities - Nasdaq
- 3 months ago - OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development - Benzinga
- 5 months ago - OSE Immunotherapeutics (ORPOF) Appoints Interim CEO Marc Le Bozec - GuruFocus
- 5 months ago - OSE Immunotherapeutics replaces CEO Nicolas Poirier, appoints Marc Le Bozec as interim CEO - Seeking Alpha